PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933327
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933327
Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of atrial fibrillation Market
The global atrial fibrillation market is experiencing steady growth, driven by the rising prevalence of cardiovascular disorders, increasing geriatric population, and continuous advancements in pharmacological therapies. Atrial fibrillation (Afib) is a cardiac arrhythmia characterized by irregular and often rapid heart rhythm, which significantly increases the risk of stroke, heart failure, and other cardiovascular complications. The condition is commonly associated with hypertension, cardiomyopathy, obesity, smoking, and advancing age, making it a growing public health concern worldwide.
In 2025, the global atrial fibrillation market size was valued at USD 17.24 billion. The market is projected to grow to USD 17.99 billion in 2026 and further reach USD 25.75 billion by 2034, exhibiting a CAGR of 4.59% from 2026 to 2034. The consistent expansion of the market reflects the increasing demand for effective long-term management therapies and improved patient access to treatment options.
Market Drivers
The rising burden of cardiovascular diseases is one of the primary factors driving market growth. According to the World Health Organization (WHO), 1.28 billion adults globally were suffering from hypertension in 2023, a key risk factor for atrial fibrillation. Structural and functional changes in the heart caused by hypertension significantly increase the likelihood of arrhythmias.
Additionally, the rapidly growing geriatric population is contributing to the rising prevalence of Afib. As per the United Nations 2023 report, the global population aged 65 years and above is projected to reach 1.6 billion by 2050, leading to higher demand for atrial fibrillation therapies. Increasing awareness, early diagnosis, and expanding access to healthcare services in developing regions are further supporting market growth.
Market Trends
A major trend shaping the market is the increasing focus on novel drug development, particularly monoclonal antibodies and Factor XI/XIa inhibitors. Key pharmaceutical players are investing heavily in innovative therapies aimed at reducing bleeding risks while maintaining anticoagulant efficacy. For instance, Anthos Therapeutics is developing abelacimab, a fully human monoclonal antibody designed to provide hemostasis-sparing anticoagulation.
Regulatory bodies are also supporting innovation by granting fast-track approvals and special designations, enabling faster clinical development and market entry of novel therapies. This trend is expected to significantly improve treatment outcomes and expand therapeutic options during the forecast period.
COVID-19 Impact
The atrial fibrillation market experienced slow growth during the COVID-19 pandemic, mainly due to supply chain disruptions, temporary clinic closures, and reduced elective procedures. According to a 2022 publication in the Journal of Clinical Medicine, there was a notable decline in catheter ablation and left atrial appendage occlusion procedures during the pandemic.
However, pharmacotherapy remained the preferred treatment approach, supporting steady drug demand. Post-pandemic recovery led to a rebound in diagnoses and treatment initiation, allowing the market to return to normal growth levels.
Restraining Factors
Despite positive growth prospects, the market faces challenges from rising product recalls and the availability of alternative treatment approaches. Product recalls due to manufacturing defects, labeling errors, and quality concerns can negatively impact brand trust and patient adherence. For example, recalls of drugs such as dofetilide and digoxin in 2023 raised safety concerns and temporarily affected market confidence, potentially shifting patient preference toward non-pharmacological interventions.
Segmentation Analysis
By drug class, the market is segmented into anticoagulants and antiarrhythmic drugs. The anticoagulants segment dominated the market, accounting for 78.92% share in 2026, driven by strong clinical guidelines and widespread adoption of direct oral anticoagulants (DOACs).
By route of administration, the oral segment led the market with an 84.98% share in 2026, owing to ease of use, better patient compliance, and a wide range of orally available drugs.
By distribution channel, retail pharmacies dominated with a 48.03% share in 2026, supported by consumer convenience, expanding pharmacy networks, and cost advantages.
Regional Insights
North America dominated the atrial fibrillation market in 2025, accounting for 38.33% market share and valued at USD 6.61 billion. The region benefits from a high disease prevalence, strong regulatory support, and a large elderly population. The U.S. market is projected to reach USD 6.14 billion by 2026.
Europe held the second-largest share, driven by increasing cardiovascular disease prevalence and strong R&D investments. Asia Pacific is projected to witness the fastest growth due to rising awareness, expanding healthcare infrastructure, and a rapidly aging population. By 2026, Japan, China, and India are projected to reach USD 0.69 billion, USD 0.89 billion, and USD 0.64 billion, respectively.
Competitive Landscape
The global market is semi-consolidated, with key players such as Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi, Pfizer, and Johnson & Johnson. These companies focus on product innovation, clinical trials, geographic expansion, and strategic collaborations to strengthen their market positions.
Conclusion
The global atrial fibrillation market is poised for steady growth, supported by the rising prevalence of cardiovascular disorders, an expanding geriatric population, and continuous advancements in drug development. Valued at USD 17.24 billion in 2025, the market is expected to grow to USD 25.75 billion by 2034. While challenges such as product recalls and alternative treatment options persist, ongoing innovation, supportive regulatory frameworks, and increasing global awareness are expected to sustain market expansion and create long-term growth opportunities.
Segmentation By Drug Class
- Anticoagulants
- Antiarrhythmic Drugs
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region
- North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- U.K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- India
- Japan
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
- 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
- 4.3. New Product Launches by Key Players
- 4.4. Impact of COVID-19 on Atrial Fibrillation Market
5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Anticoagulants
- 5.1.2. Anti-arrhythmic Drugs
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Intravenous
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Online Pharmacies
- 5.3.3. Retail Pharmacies
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Anticoagulants
- 6.1.2. Anti-arrhythmic Drugs
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Intravenous
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Online Pharmacies
- 6.3.3. Retail Pharmacies
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.1.1. By Drug Class
- 6.4.2. Canada
- 6.4.2.1. By Drug Class
- 6.4.1. U.S.
7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Anticoagulants
- 7.1.2. Anti-arrhythmic Drugs
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Intravenous
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Online Pharmacies
- 7.3.3. Retail Pharmacies
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.4.1. Germany
- 7.4.1.1. By Drug Class
- 7.4.2. U.K.
- 7.4.2.1. By Drug Class
- 7.4.3. France
- 7.4.3.1. By Drug Class
- 7.4.4. Spain
- 7.4.4.1. By Drug Class
- 7.4.5. Italy
- 7.4.5.1. By Drug Class
- 7.4.6. Scandinavia
- 7.4.6.1. By Drug Class
- 7.4.7. Rest of Europe
- 7.4.7.1. By Drug Class
- 7.4.1. Germany
8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Anticoagulants
- 8.1.2. Anti-arrhythmic Drugs
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Intravenous
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Online Pharmacies
- 8.3.3. Retail Pharmacies
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Drug Class
- 8.4.2. China
- 8.4.2.1. By Drug Class
- 8.4.3. India
- 8.4.3.1. By Drug Class
- 8.4.4. Australia
- 8.4.4.1. By Drug Class
- 8.4.5. Southeast Asia
- 8.4.5.1. By Drug Class
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Drug Class
- 8.4.1. Japan
9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Anticoagulants
- 9.1.2. Anti-arrhythmic Drugs
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Intravenous
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Online Pharmacies
- 9.3.3. Retail Pharmacies
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Drug Class
- 9.4.2. Mexico
- 9.4.2.1. By Drug Class
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Drug Class
- 9.4.1. Brazil
10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Anticoagulants
- 10.1.2. Anti-arrhythmic Drugs
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Intravenous
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Online Pharmacies
- 10.3.3. Retail Pharmacies
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Drug Class
- 10.4.2. South Africa
- 10.4.2.1. By Drug Class
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Drug Class
- 10.4.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Bristol-Myers Squibb Company
- 11.2.1.1. Overview
- 11.2.1.2. Product
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. Sanofi
- 11.2.2.1. Overview
- 11.2.2.2. Product
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Eisai Co., Ltd.
- 11.2.3.1. Overview
- 11.2.3.2. Product
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. Johnson & Johnson
- 11.2.4.1. Overview
- 11.2.4.2. Product
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Daiichi Sankyo, Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Product
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. Par Pharmaceutical
- 11.2.6.1. Overview
- 11.2.6.2. Product
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. Bayer AG
- 11.2.7.1. Overview
- 11.2.7.2. Product
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. Pfizer Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Product
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (Based on Availability)
- 11.2.1. Bristol-Myers Squibb Company
List of Tables
- Table 1: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 6: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 7: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: U.S. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 10: Canada Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 11: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 12: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 13: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 14: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 15: Germany Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 16: U.K. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 17: France Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 18: Italy Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 19: Spain Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 20: Scandinavia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 21: Rest of Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 22: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 23: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 24: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 25: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Japan Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 27: India Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 28: China Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 29: Australia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 30: Southeast Asia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 31: Rest of Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 32: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 33: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 34: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 35: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 36: Brazil Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 37: Mexico Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 38: Rest of Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 39: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 40: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 41: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 42: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 43: GCC Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 44: South Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 45: Rest of Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
List of Figures
- Figure 1: Global Atrial Fibrillation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Atrial Fibrillation Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 5: Global Atrial Fibrillation Market Value Share (%), by Region, 2025 & 2034
- Figure 6: North America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 7: North America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
- Figure 8: North America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 9: North America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
- Figure 10: North America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: North America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America Atrial Fibrillation Market Value (USD billion), By Country, 2025 & 2034
- Figure 13: North America Atrial Fibrillation Market Value Share (%), By Country, 2025
- Figure 14: Europe Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 15: Europe Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
- Figure 16: Europe Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 17: Europe Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
- Figure 18: Europe Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 19: Europe Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 21: Europe Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 23: Asia Pacific Atrial Fibrillation Market Value Share (%), by Drug Class y, 2025
- Figure 24: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 25: Asia Pacific Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
- Figure 26: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 27: Asia Pacific Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 29: Asia Pacific Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
- Figure 30: Latin America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 31: Latin America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
- Figure 32: Latin America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 33: Latin America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
- Figure 34: Latin America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 35: Latin America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Latin America Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 37: Latin America Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
- Figure 38: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 39: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
- Figure 40: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 41: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
- Figure 42: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 43: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
- Figure 44: Middle East & Africa Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 45: Middle East & Africa Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
- Figure 46: Global Atrial Fibrillation Market Share (%), By Company, 2025
